BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35180489)

  • 1. Structure-based discovery of a specific SHP2 inhibitor with enhanced blood-brain barrier penetration from PubChem database.
    Ma Y; Li WY; Sun T; Zhang L; Lu XH; Yang B; Wang RL
    Bioorg Chem; 2022 Apr; 121():105648. PubMed ID: 35180489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation.
    Li WY; Ma Y; Li HX; Lu XH; Du S; Ma YC; Zhou L; Wang RL
    Bioorg Chem; 2020 Dec; 105():104391. PubMed ID: 33113413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
    Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
    ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.
    Wu X; Xu G; Li X; Xu W; Li Q; Liu W; Kirby KA; Loh ML; Li J; Sarafianos SG; Qu CK
    J Med Chem; 2019 Feb; 62(3):1125-1137. PubMed ID: 30457860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
    Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
    Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.
    Luo R; Fu W; Shao J; Ma L; Shuai S; Xu Y; Jiang Z; Ye Z; Zheng L; Zheng L; Yu J; Zhang Y; Yin L; Tu L; Lv X; Li J; Liang G; Chen L
    Eur J Med Chem; 2023 May; 253():115305. PubMed ID: 37023678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
    Liu WS; Yang B; Wang RR; Li WY; Ma YC; Zhou L; Du S; Ma Y; Wang RL
    Bioorg Chem; 2020 Jul; 100():103875. PubMed ID: 32380342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of demethylincisterol A
    Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
    Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, activity and molecular dynamics studies of 1,3,4-thiadiazole derivatives as selective allosteric inhibitors of SHP2 for the treatment of cancer.
    Liu WS; Zhao JF; Guo XJ; Lu SZ; Li W; Li WZ
    Eur J Med Chem; 2023 Oct; 258():115585. PubMed ID: 37390510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers.
    Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
    J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
    Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
    J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects.
    Lade DM; Nicoletti R; Mersch J; Agazie YM
    Eur J Med Chem; 2023 Feb; 247():115017. PubMed ID: 36584630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2).
    Kwon SJ; Ahn D; Yang HM; Kang HJ; Chung SJ
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
    Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
    J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).
    Liu W; Yu B; Xu G; Xu WR; Loh ML; Tang LD; Qu CK
    J Med Chem; 2013 Sep; 56(18):7212-21. PubMed ID: 23957426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Discovery of Potent SHP2 Inhibitors with Anti-Proliferative Activity in Breast Cancer Cell Lines.
    Ghemrawi R; Khair M; Hasan S; Aldulaymi R; AlNeyadi SS; Atatreh N; Ghattas MA
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A procedure combining molecular docking and semiempirical method PM7 for identification of selective Shp2 inhibitors.
    Rocha SFLS; Sant'Anna CMR
    Biopolymers; 2019 Nov; 110(11):e23320. PubMed ID: 31268558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
    Mitra R; Ayyannan SR
    ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.